✉ Email this page to a colleague
« Back to Dashboard
▶ Start for $1
Remove trial restrictions
Zamicastat is an investigational drug.
There have been 11 clinical trials for Zamicastat. The most recent clinical trial was a Phase 2 trial, which was initiated on June 6th 2019.
The most common disease conditions in clinical trials are Hypertension, Pulmonary Arterial Hypertension, and Familial Primary Pulmonary Hypertension. The leading clinical trial sponsors are Bial - Portela C S.A., Covance, and [disabled in preview].
There are eleven US patents protecting this investigational drug and one hundred and twenty-six international patents.
Recent Clinical Trials for Zamicastat
|Pharmacokinetics, Safety and Efficacy of BIA 5-1058 in PAH||Bial - Portela C S.A.||Phase 2|
|Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of BIA 5-1058||Bial - Portela C S.A.||Phase 1|
|Effect of BIA 5 1058 on Cardiac Repolarization||Covance||Phase 1|
Top disease conditions for Zamicastat
Top clinical trial sponsors for Zamicastat
|Drugname||Patent Number||Patent Title||Patent Assignee||Estimated Expiration|
|Zamicastat||See Plans and Pricing||Process for preparing 1,3-dihydroimidazole-2-thione derivatives||Bial-Portela & CA, S.A. (S. Mamede do Coronado, PT)||See Plans and Pricing|
|Zamicastat||See Plans and Pricing||Controlled release dosage form||TRIASTEK, INC. (Nanjing, CN)||See Plans and Pricing|
|Zamicastat||See Plans and Pricing||Oral drug dosage forms having desired drug release profiles and uses thereof||Triastek, Inc. (Nanjing, CN)||See Plans and Pricing|
|Zamicastat||See Plans and Pricing||1,3-dihydroimidazole-2-thione derivatives for use in the treatment of pulmonary arterial hypertension and lung injury||Bial-Portela & CA, S.A. (S. Mamede do Coronado, PT)||See Plans and Pricing|
|Zamicastat||See Plans and Pricing||Processes for preparing medicaments for the treatment of cardiovascular diseases and intermediates for use therein||Bial-Portela & CA, S.A. (S. Mamede do Coronado, PT)||See Plans and Pricing|
|>Drugname||>Patent Number||>Patent Title||>Patent Assignee||>Estimated Expiration|
|Drugname||Country||Document Number||Estimated Expiration||Related US Patent|
|Zamicastat||European Patent Office||EP2726454||2031-06-29||See Plans and Pricing|
|Zamicastat||Spain||ES2667099||2031-06-29||See Plans and Pricing|
|Zamicastat||Japan||JP2014520796||2031-06-29||See Plans and Pricing|
|Zamicastat||Japan||JP5981539||2031-06-29||See Plans and Pricing|
|Zamicastat||Portugal||PT2726454||2031-06-29||See Plans and Pricing|
|>Drugname||>Country||>Document Number||>Estimated Expiration||>Related US Patent|